23 Mar Phase 2 FMT‑LUMINate trial meets primary endpoint and points to “loss of deleterious taxa” as a key mechanism in microbiome‑enabled immunotherapy
Posted at 11:06h
in Uncategorized
Immune checkpoint inhibitors (ICIs) have improved outcomes in NSCLC and melanoma, yet many patients still show primary resistance. The phase 2, multicenter, open‑label FMT‑LUMINate trial evaluated whether a single oral FMT from a healthy donor, administered before ICI initiation, could enhance first‑line treatment efficacy. Clinical activityNSCLC cohort...
